Recently, PCSK9 inhibitors were discovered as a novel therapy for dyslipidemia; preventing LDLR degradation, thus, producing a substantial reduction of LDL-C levels in the bloodstream and decreasing the risk of cardiovascular diseases (22). The gene discussed is PCSK9; the disease is metabolic syndrome.